glp 1 receptor agonist names The glucagon-like peptide agonists (GLP-1 RAs) currently Outpatient Sedation Basics for Patients

In the initial study of semaglutide, in the second year patients lost on average an extra 8% of their body weight

for diabetes vs

That's not a technicality - it's a meaningful regulatory distinction that every patient in this category should understand before starting treatment

The results, which appear March 18 in BMJ Medicine, show that the consequences of stopping GLP-1 drugs go beyond weight regain, extending to increased cardiovascular risk, and underscore the importance of continuous treatment for sustained heart protection

For NPs, these broad effects highlight the importance of aligning drug selection with individual patient profiles while monitoring metabolic response and overall health outcomes

If you're already a GLP-1 user, you likely already know alllll about them